- Home
- ADPT vs STGW Comparison
ADPT vs STGW Comparison
Compare ADPT & STGW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADPT
- STGW
- Stock Information
- Founded
- ADPT 2009
- STGW 1980
- Country
- ADPT United States
- STGW United States
- Employees
- ADPT N/A
- STGW N/A
- Industry
- ADPT Biotechnology: Biological Products (No Diagnostic Substances)
- STGW
- Sector
- ADPT Health Care
- STGW
- Exchange
- ADPT Nasdaq
- STGW Nasdaq
- Market Cap
- ADPT 1.8B
- STGW 1.4B
- IPO Year
- ADPT 2019
- STGW N/A
- Fundamental
- Price
- ADPT $12.61
- STGW $5.23
- Analyst Decision
- ADPT Strong Buy
- STGW Buy
- Analyst Count
- ADPT 8
- STGW 5
- Target Price
- ADPT $12.38
- STGW $8.17
- AVG Volume (30 Days)
- ADPT 1.8M
- STGW 990.4K
- Earning Date
- ADPT 11-06-2025
- STGW 11-06-2025
- Dividend Yield
- ADPT N/A
- STGW N/A
- EPS Growth
- ADPT N/A
- STGW N/A
- EPS
- ADPT N/A
- STGW N/A
- Revenue
- ADPT $205,216,000.00
- STGW $2,858,547,000.00
- Revenue This Year
- ADPT $32.76
- STGW $4.81
- Revenue Next Year
- ADPT $15.81
- STGW $8.73
- P/E Ratio
- ADPT N/A
- STGW N/A
- Revenue Growth
- ADPT 21.60
- STGW 9.37
- 52 Week Low
- ADPT $3.98
- STGW $4.03
- 52 Week High
- ADPT $13.68
- STGW $8.18
- Technical
- Relative Strength Index (RSI)
- ADPT 51.14
- STGW 41.81
- Support Level
- ADPT $12.34
- STGW $5.33
- Resistance Level
- ADPT $13.68
- STGW $5.62
- Average True Range (ATR)
- ADPT 0.56
- STGW 0.18
- MACD
- ADPT -0.08
- STGW -0.05
- Stochastic Oscillator
- ADPT 20.15
- STGW 5.17
About ADPT Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).
About STGW Stagwell Inc.
Stagwell Inc is the challenger holding company built to transform marketing. It delivers scaled creative performance for the world's ambitious brands, connecting culture-moving creativity with a technology to harmonize the art and science of marketing. The company's segments include Integrated Agencies Network; Brand Performance Network; and Communications Network. It generates maximum revenue from the Integrated Agencies Network segment. Geographically, it derives a majority of its revenue from the United States.